The U.S. Food and Drug Administration approved expanded use of AstraZeneca Plc’s cancer drug Lynparza.

Pfizer’s talazoparib for advanced breast cancer was demonstrated to be superior to chemotherapy in a late-stage study.

Tesaro Inc.’s PARP inhibitor Zejula was approved by the European Commission for recurrent ovarian cancer.

Clovis Oncology Inc. announced the first presentation of a comprehensive dataset from the company’s Phase 3 ARIEL3 study of rucaparib at the 2017 European Society for Medical Oncology (ESMO) Congress in Madrid.

The FDA expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co. Inc., and approved a new two-tablet regimen for the drug.

There is a ray of sunshine for beleaguered Tesaro as Japanese pharma giant Takeda Pharmaceutical struck a deal worth up to $340 million for Asian development and marketing rights for recently approved PARP inhibitor Zejula (niraparib).

Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.

Clovis Oncology announced topline results from a confirmatory Phase III ARIEL3 trial of Rubraca (ruparib) in platinum-sensitive ovarian cancer.

Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.

Women with advanced breast cancer who carry specific genetic mutations experienced double the response rate and delayed disease progression when treated with AstraZeneca’s Lynparza versus standard chemotherapy, according to a late-stage trial.